IDH2 is altered in 10.54% of acute myeloid leukemia patients [3].

IDH2 is an inclusion criterion in 20 clinical trials for acute myeloid leukemia, of which 19 are open and 1 is closed. Of the trials that contain IDH2 status and acute myeloid leukemia as inclusion criteria, 4 are phase 1 (4 open), 6 are phase 1/phase 2 (6 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [4].

Enasidenib has evidence of efficacy in patients with IDH2 mutation in acute myeloid leukemia [4].

IDH2 is altered in 4.88% of myelodysplastic syndromes patients [3].

IDH2 is an inclusion criterion in 8 clinical trials for myelodysplastic syndromes, of which 8 are open and 0 are closed. Of the trials that contain IDH2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

IDH2 is altered in 2.3% of glioma patients [3].

IDH2 is an inclusion criterion in 8 clinical trials for glioma, of which 6 are open and 2 are closed. Of the trials that contain IDH2 status and glioma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (4 open) [4].

IDH2 is altered in 1.02% of malignant solid tumor patients [3].

IDH2 is an inclusion criterion in 8 clinical trials for malignant solid tumor, of which 6 are open and 2 are closed. Of the trials that contain IDH2 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open) [4].

IDH2 is altered in 1.92% of malignant glioma patients [3].

IDH2 is an inclusion criterion in 5 clinical trials for malignant glioma, of which 5 are open and 0 are closed. Of the trials that contain IDH2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

IDH2 is altered in 5.61% of chronic myelomonocytic leukemia patients [3].

IDH2 is an inclusion criterion in 4 clinical trials for chronic myelomonocytic leukemia, of which 4 are open and 0 are closed. Of the trials that contain IDH2 status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

IDH2 is altered in 1.49% of myeloproliferative neoplasm patients [3].

IDH2 is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 4 are open and 0 are closed. Of the trials that contain IDH2 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

IDH2 is altered in 9.88% of WHO grade II glioma patients [3].

IDH2 is an inclusion criterion in 3 clinical trials for WHO grade II glioma, of which 3 are open and 0 are closed. Of the trials that contain IDH2 status and WHO grade II glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

IDH2 is altered in 3.57% of cholangiocarcinoma patients [3].

IDH2 is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain IDH2 status and cholangiocarcinoma as inclusion criteria, 3 are phase 2 (2 open) [4].

IDH2 is altered in 1.57% of anaplastic astrocytoma patients [3].

IDH2 is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain IDH2 status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [4].

IDH2 is altered in 13.33% of oligodendroglioma patients [3].

IDH2 is an inclusion criterion in 2 clinical trials for oligodendroglioma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and oligodendroglioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

IDH2 is altered in 4.37% of WHO grade III glioma patients [3].

IDH2 is an inclusion criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

IDH2 is altered in 2.17% of diffuse astrocytoma patients [3].

IDH2 is an inclusion criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

IDH2 is altered in 1.26% of astrocytoma patients [3].

IDH2 is an inclusion criterion in 2 clinical trials for astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and astrocytoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

IDH2 is altered in 1.1% of breast carcinoma patients [3].

IDH2 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH2 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain IDH2 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

IDH2 is altered in 14.67% of angioimmunoblastic T-cell lymphoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

IDH2 is altered in 14.4% of myelodysplastic syndrome with excess blasts-2 patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 13.33% of anaplastic oligodendroglioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 9.46% of leukemia patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 7.14% of oligoastrocytoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and oligoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 6.98% of low grade glioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [4].

IDH2 is altered in 6.94% of myeloid neoplasm patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 6.02% of secondary acute myeloid leukemia patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 6.02% of therapy-related acute myeloid leukemia patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 5.48% of mixed glioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for mixed glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and mixed glioma as inclusion criteria, 1 is phase 3 (1 open) [4].

IDH2 is altered in 5.35% of hematopoietic and lymphoid malignancy patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 3.73% of myelodysplastic/myeloproliferative neoplasm patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 2.65% of primary myelofibrosis patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 2.74% of diffuse glioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 2.41% of myelofibrosis patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH2 is altered in 2.0% of polycythemia vera, post-polycythemic myelofibrosis phase patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.98% of high-grade glioma, NOS patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.84% of essential thrombocythemia patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.35% of lymphoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 1.14% of polycythemia vera patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 1.32% of meningioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and meningioma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 1.23% of glioblastoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is altered in 0.93% of primary brain neoplasm patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and primary brain neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 1.18% of gastric carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 0.67% of clear cell renal cell carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 1.14% of ovarian carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 0.55% of non-small cell lung carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 0.41% of renal cell carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 0.38% of gallbladder carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH2 is altered in 0.48% of pancreatic carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is altered in 0.74% of gastrointestinal stromal tumor patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 0.2% of pleural mesothelioma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is altered in 0.24% of prostate carcinoma patients [3].

IDH2 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH2 is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [4].